Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group

被引:224
|
作者
Osoba, D
Beziak, A
Brundage, M
Zee, B
Tu, DS
Pater, J
机构
[1] QOL Consulting, W Vancouver, BC V7W 3H7, Canada
[2] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada
[3] Queens Univ, CTG, NCIC, Kingston, ON, Canada
[4] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
关键词
health-related quality of life; analysis; interpretation; clinical trials;
D O I
10.1016/j.ejca.2004.10.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Clinicians are being confronted with increasing amounts of health-related quality of life (HRQOL) data. Thus, there is a need for a greater understanding of the analysis and interpretation of HRQOL so that the data can be reported in an appropriate manner. The approach of the Clinical Trials Group of the National Cancer Institute of Canada emphasises the clinical meaning of the results, while avoiding complex statistical modelling. It consists of four steps: calculating the questionnaire completion rates, calculating the baseline scores, determining the individual change in scores over time for the domains specified in the trial hypothesis, and culminates in determining the proportions of patients who have reported clinically meaningful changes in scores since baseline. A rationale supporting each step is given. This approach is presented as a simple and practical aid to the analysis, interpretation and reporting of HRQOL results. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:280 / 287
页数:8
相关论文
共 50 条
  • [31] Factors affecting workload of cancer clinical trials: Results of a multicenter study of the National Cancer Institute of Canada Clinical Trials Group
    Roche, K
    Paul, N
    Smuck, B
    Whitehead, M
    Zee, B
    Pater, J
    Hiatt, MA
    Walker, H
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (02) : 545 - 556
  • [32] Health-Related Quality of Life and Participation in Osteoporosis Clinical Trials
    C. R. Kessenich
    G. H. Guyatt
    C. J. Rosen
    Calcified Tissue International, 1998, 62 : 189 - 192
  • [33] Pediatric health-related quality of life questionnaires in clinical trials
    Raat, H
    Mohangoo, AD
    Grootenhuis, MA
    CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 6 (03) : 180 - 185
  • [34] Principles of health-related quality of life: Assessment in clinical trials
    Cramer, JA
    EPILEPSIA, 2002, 43 (09) : 1084 - 1095
  • [35] TESTING HYPOTHESES IN CLINICAL-TRIALS - EXPERIENCE OF THE NATIONAL-CANCER-INSTITUTE-OF-CANADA CLINICAL-TRIALS GROUP
    PATER, JL
    EISENHAUER, E
    SHELLEY, W
    WILLAN, AR
    CANCER TREATMENT REPORTS, 1986, 70 (09): : 1133 - 1136
  • [36] Item response models for the longitudinal analysis of health-related quality of life in cancer clinical trials
    Barbieri, Antoine
    Peyhardi, Jean
    Conroy, Thierry
    Gourgou, Sophie
    Lavergne, Christian
    Mollevi, Caroline
    BMC MEDICAL RESEARCH METHODOLOGY, 2017, 17
  • [37] Item response models for the longitudinal analysis of health-related quality of life in cancer clinical trials
    Antoine Barbieri
    Jean Peyhardi
    Thierry Conroy
    Sophie Gourgou
    Christian Lavergne
    Caroline Mollevi
    BMC Medical Research Methodology, 17
  • [38] Venous Thromboembolism and Nonsmall Cell Lung Cancer A Pooled Analysis of National Cancer Institute of Canada Clinical Trials Group Trials
    Hicks, Lisa K.
    Cheung, Matthew C.
    Ding, Keyue
    Hasan, Baktiar
    Seymour, Lesley
    Le Maitre, Aurelie
    Leighl, Natasha B.
    Shepherd, Frances A.
    CANCER, 2009, 115 (23) : 5516 - 5525
  • [39] A Comparative Review of Health-Related Quality-of-Life Measures for Use in HIV/AIDS Clinical Trials
    Darren J. Clayson
    Diane J. Wild
    Paul Quarterman
    Isabelle Duprat-Lomon
    Maria Kubin
    Stephen Joel Coons
    PharmacoEconomics, 2006, 24 : 751 - 765
  • [40] Health-related quality-of-life as co-primary endpoint in randomized clinical trials in oncology
    Fiteni, Frederic
    Pam, Alhousseiny
    Anota, Amelie
    Vernerey, Dewi
    Paget-Bailly, Sophie
    Westeel, Virginie
    Bonnetain, Franck
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (08) : 885 - 891